文献速递肾移植

质子泵抑制剂使用与肾移植受者髋部骨折风险

Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients.
PubMed 文献 · Am J Kidney Dis · 2016-11-17

基于美国肾脏数据系统的病例对照研究,纳入231例首次髋部骨折的肾移植受者,按年龄、性别、种族和移植年份匹配15,575例对照。校正基线人口学、临床和药物协变量后,任何PPI使用与髋部骨折风险相关(OR 1.39,95%CI 1.04-1.84),较高PPI使用亦相关(OR 1.41,95%CI 1.02-1.95)。

要点

  • 肾移植受者中,任何PPI使用与髋部骨折风险相关,校正后OR 1.39(95%CI 1.04-1.84)。
  • 较高PPI使用(一年中>80%时间处方PPI)校正后OR 1.41(95%CI 1.02-1.95)。
  • 病例中65.4%在索引日前一年内被处方PPI,对照中为57.4%。

核心结论

  • 在美国肾移植人群中,PPI使用与髋部骨折风险相关。

研究设计与样本

  • 病例对照研究,从美国肾脏数据系统通过诊断和操作识别231例首次髋部骨折的肾移植受者。
  • 病例按髋部骨折索引日期与15,575例对照在年龄、性别、种族和移植年份上进行匹配。

主要发现

  • 索引日前一年内,病例中65.4%被处方PPI,对照中57.4%。
  • 病例中34.6%在索引日前一年内>80%时间被处方PPI(较高PPI使用者),对照中28.9%。
  • 任何PPI使用与髋部骨折的未校正OR为1.55(95%CI 1.18-2.05),较高PPI使用为1.65(95%CI 1.2-2.27)。
  • 校正基线人口学、临床和药物协变量后,任何PPI使用与髋部骨折仍相关,OR 1.39(95%CI 1.04-1.84)。
  • 校正后较高PPI使用与髋部骨折仍相关,OR 1.41(95%CI 1.02-1.95)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 潜在残余混杂,源于错误确定或不可获得的混杂因素。
  • 队列仅限于接受低收入补贴的医疗保险受益人。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posttransplantation bone disease is a significant problem, with few well-evidenced therapeutic options. Proton pump inhibitors (PPIs) are associated with hip fracture in the general population and are widely prescribed for kidney transplant recipients. STUDY DESIGN: A case-control study. SETTING & PARTICIPANTS: From the US Renal Data System, we identified from diagnoses and procedures 231 kidney transplant recipients with a first hip fracture. Cases were matched at the hip fracture index date with 15,575 controls on age, sex, race, and transplantation year. PREDICTOR: PPI use. OUTCOMES: First hip fracture. RESULTS: In the year prior to the index date, a PPI was prescribed to 65.4% of cases and 57.4% of controls. Additionally, in 34.6% of cases and 28.9% of controls, a PPI was prescribed for >80% of the year preceding the index date (higher PPI users). Unadjusted ORs of hip fracture associated with any and higher PPI use were 1.55 (95% CI, 1.18-2.05) and 1.65 (95% CI, 1.2-2.27), respectively. When adjusted for baseline demographic, clinical, and pharmacologic covariables, any and higher PPI use remained associated with hip fracture, with ORs of 1.39 (95% CI, 1.04-1.84) and 1.41 (95% CI, 1.02-1.95), respectively. LIMITATIONS: Potential residual confounding through either incorrectly ascertained or unavailable confounders; cohort limited to Medicare beneficiaries receiving low-income subsidy. CONCLUSIONS: In summary, PPI use was associated with hip fracture risk in the US kidney transplant population.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lenihan CR, Sukumaran Nair S, Vangala C, et al. Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients. Am J Kidney Dis. 2016. PMID: 27866965. doi:10.1053/j.ajkd.2016.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。